Trusted Resources: News & Meetings
Latest announcements and gatherings
Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease
Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.
“These analyses provide insight into both the short-term and long-term efficacy and safety of teprotumumab and are clinically relevant as all objective signs and symptoms of thyroid eye disease, especially proptosis and diplopia, which can be resistant to medical therapy, were markedly and significantly improved with teprotumumab,” George J. Kahaly, MD, PhD, a professor of medicine, endocrinology and metabolism at Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues wrote in a study published in The Lancet Diabetes & Endocrinology.
myBinderRelated Content
-
Anthony Maloof, MBBS hons, MBiomedE, FRANZCODr. Maloof is an internationally recogni...
-
Understanding Thyroid Eye DiseaseThyroid eye disease causes the muscles a...
-
Meta-Analysis of Methylprednisolone Pulse Therapy for Graves’ OphthalmopathyA meta-analysis was performed to evaluat...
-
Sensitivity and Responsiveness of the Patient-Reported TED-QOL to Rehabilitative Surgery in Thyroid Eye DiseaseWe tested the sensitivity and responsive...
-
Clinical Implications of Immunoglobulin G4 to Graves’ OphthalmopathyBackground: This study aimed to explore...
-
Eric Hink, MDEric Hink is Associate Professor of opht...
-
No Need to Suffer From Double Vision With Graves’ Diseasehttps://www.youtube.com/watch?v=cQ7-Yi5t...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google